VYNE Therapeutics Inc.
$0.63
▼
-0.83%
2026-04-21 10:12:01
vynetherapeutics.com
NCM: VYNE
Explore VYNE Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$20.33 M
Current Price
$0.63
52W High / Low
$1.99 / $0.28
Stock P/E
—
Book Value
$0.83
Dividend Yield
—
ROCE
-107.15%
ROE
-66.96%
Face Value
—
EPS
$-0.63
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
10
Beta
1.95
Debt / Equity
0
Current Ratio
12.53
Quick Ratio
12.53
Forward P/E
-0.37
Price / Sales
35.66
Enterprise Value
$-8.68 M
EV / EBITDA
0.29
EV / Revenue
-15.23
Rating
None
Target Price
$2
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Mineralys Therapeutics, Inc. | $30.07 | — | $2.52 B | — | -26.38% | -36.91% | $47.65 / $12.59 | $7.93 |
| 2. | Absci Corporation | $3.95 | — | $547.82 M | — | -64.8% | -62.5% | $5.23 / $2.24 | $1.25 |
| 3. | Creative Medical Technology Holdings, Inc. | $2.26 | — | $9.13 M | — | -81.64% | -86.47% | $6.25 / $1.5 | $2.03 |
| 4. | Tectonic Therapeutic, Inc. | $28.76 | — | $554.1 M | — | -33.43% | -37.82% | $36.03 / $14.39 | $13.41 |
| 5. | Novavax, Inc. | $8.67 | 3.2 | $1.41 B | — | 76.84% | -117.16% | $11.97 / $5.8 | $-0.79 |
| 6. | Enanta Pharmaceuticals, Inc. | $13.78 | — | $409.17 M | — | -36.76% | -60.01% | $17.15 / $4.83 | $4.36 |
| 7. | Telomir Pharmaceuticals, Inc. | $1.48 | — | $49.85 M | — | -178.22% | -3.18% | $3.1 / $1.05 | $0.17 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.13 M | 0.17 M | 0.07 M | 0.2 M | 0.08 M | — |
| Operating Profit | -5.22 M | -7.79 M | -7.54 M | -9.2 M | -12.77 M | — |
| Net Profit | -4.84 M | -7.28 M | -5.75 M | -8.61 M | -12.02 M | — |
| EPS in Rs | -0.15 | -0.22 | -0.17 | -0.26 | -0.36 | -0.29 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.57 M | 0.5 M | 0.42 M | 0.48 M |
| Operating Profit | -29.75 M | -43.64 M | -29.26 M | -34.3 M |
| Net Profit | -26.48 M | -39.83 M | -28.45 M | -23.21 M |
| EPS in Rs | -0.79 | -1.2 | -0.85 | -0.7 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 30.16 M | 66.91 M | 97.69 M | 40.76 M |
| Total Liabilities | 2.4 M | 14.82 M | 8.95 M | 9.56 M |
| Equity | 27.77 M | 52.09 M | 88.73 M | 31.2 M |
| Current Assets | 30.01 M | 64.44 M | 95.96 M | 38.27 M |
| Current Liabilities | 2.4 M | 14.82 M | 7.54 M | 9.35 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -33.12 M | -33.97 M | -25.34 M | -29.2 M |
| Investing CF | 37.37 M | 23.36 M | -57.35 M | 15.67 M |
| Financing CF | -0.14 M | -0.14 M | 82.39 M | 1.65 M |
| Free CF | -33.12 M | -34.09 M | -25.34 M | -29.2 M |
| Capex | — | -0.12 M | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 18.16% | -11.11% | — | — |
| Earnings Growth % | -40% | -22.59% | — | — |
| Profit Margin % | -7950.9% | -6710.38% | -4865.83% | — |
| Operating Margin % | -8709.98% | -6900.47% | -7189.73% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -8709.18% | -6900.47% | -7174.63% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-02-13 | 1:0.0555556 |